Complete clonal loss of SNAI2 is uncommon in prostate cancer, being reported in 0.6% of localized cases in The Cancer Genome Atlas cohort.24 Similarly, in our analysis, SNAI2 loss was only identified subclonally, and on FISH analysis, biallelic loss was only observed in up to a maximum of 30% of cells, even in extreme responders. This evidence concerns the gene SNAI2 and prostate cancer.